Tokyo Tape
Sign in
← CellSeed

Half-year report · Q2

7776.TEDINET S100U7CG
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥76m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥190m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥67m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥464m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥359m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥463m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥710m2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥367m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥473m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥363m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥474m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥847m2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥364m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥2.4bnat 2024-06-30StandaloneAssets
Total assets¥2.5bnat 2023-12-31StandaloneAssets
Total assets¥2.0bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥311mat 2024-06-30StandaloneLiabilities
Total liabilities¥301mat 2023-12-31StandaloneLiabilities
Net assets / equity¥2.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥2.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.7bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥2.2bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥2.2bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.6bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥405m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥779m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥348m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥6m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥56m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥18m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥422m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥848m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-14.742024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-29.432023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.292023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio86.4%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio86.9%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.1%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued33,447,119at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued31,459,019at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,385,419at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥113m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2024-01-01 → 2024-06-30¥1m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2024-01-01 → 2024-06-30¥1m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2024-01-01 → 2024-06-30−¥332m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2024-01-01 → 2024-06-30¥75m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2024-01-01 → 2024-06-30¥75m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥19m
—segment totalrevenue2024-01-01 → 2024-06-30¥76m
—segment totalrevenue external2024-01-01 → 2024-06-30¥76m
—segment totalsegment profit2024-01-01 → 2024-06-30−¥351m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥96m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2023-01-01 → 2023-06-30¥5m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2023-01-01 → 2023-06-30¥5m
jpcrp040300-q2r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2023-01-01 → 2023-06-30−¥236m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2023-01-01 → 2023-06-30¥62m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2023-01-01 → 2023-06-30¥62m
jpcrp040300-q2r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥28m
—segment totalrevenue2023-01-01 → 2023-06-30¥67m
—segment totalrevenue external2023-01-01 → 2023-06-30¥67m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥263m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 433
ItemContextValueUnit
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember76303000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember76303000JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember75086000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember1217000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember76303000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember76303000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember-18715000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember-332108000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember-350824000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember-113346000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-464170000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第24期中（自　2024年１月１日　至　2024年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社セルシード
Company name in english cover pageFilingDateInstantCellSeed Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　橋本　せつ子
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都江東区青海二丁目５番10号テレコムセンタービル
Telephone number address of registered headquarter cover pageFilingDateInstant03-6380-7490
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経営管理部長　　　畑中　格
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都江東区青海二丁目５番10号テレコムセンタービル
Telephone number nearest place of contact cover pageFilingDateInstant03-6380-7490
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経営管理部長　　　畑中　格
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE24158
Fund codeFilingDateInstant－
Security codeFilingDateInstant77760
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社セルシード
Filer name in englishFilingDateInstantCellSeed Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2024-01-01
Current period end dateFilingDateInstant2024-06-30
Type of current periodFilingDateInstantQ2

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass